Skip to main content

Search

Neuroscience

Neuroscience
Oncology

One in four of us will be affected by a mental health disorder in our lifetime.1 We are determined to continue to increase our understanding of mental illness by supporting and engaging with those in need through open dialogue and innovative treatments.

Despite advances in our understanding of neurological and mental disorders, improving treatments and care remains challenging due to the complexity and diversity of conditions, and gaps in research on the biological basis of these disorders. Neurological and mental disorders, such as depression and schizophrenia, can be experienced in isolation, or as co-morbidities of other conditions.2 In addition to physical and psychological symptoms, they may also affect employment and education, relationships, health and overall quality of life.3 People living with these conditions often experience negative consequences from the stigma that exists in society, and the burden not only impacts those affected but also their loved ones and caregivers.     

Our Goal

 
Our Goal

We want to reduce the burden, disability and devastation caused by serious neuropsychiatric and neurodegenerative diseases.

Our mission is to develop new solutions and innovations that not only improve, but transform, the lives of people living with mental illness.

We are committed to improving the way in which mental health disorders are prevented, diagnosed and treated in order to change the lives of people living with mental illness.

 
Our Commitment to Patients

Commitment to Patients

Our ultimate responsibility remains with our patients.

We recognise the heartbreak that these conditions can cause for those affected and their loved ones. The burden and impact of mental illness are vast.

That’s why ongoing dialogue with patients and their carers is important to enhance our understanding of living with mental health conditions. Because it’s through understanding mental illness from the perspective of those living with these conditions that we’re better able to help.

We work with patient groups and organisations to continually build on our understanding of living with mental health conditions. We ensure that the insights we gather through open and ongoing dialogue with patients are incorporated into disease area strategies.

Our Proud Heritage

At Janssen, we are focused on pushing the boundaries of medicine to help resolve some of the most challenging medical conditions of our time. Mental health has been an important part of our heritage since our company was founded and we remain committed to reducing the burden, disability and devastation caused by mental health disorders.

We are immensely proud of the many ground-breaking mental health products Janssen has pioneered over the course of our 60+ year legacy in the field.

Our Disease Areas of Focus

Schizophrenia is a disorder of the mind that affects how you think, feel and behave. About 1 in 100 people will suffer an episode of schizophrenia at some point during their life.4 It causes a range of different psychological symptoms, including hallucinations, delusions, muddled thoughts, and changes in behaviour. Without effective treatment, it is a persistent and detrimental condition that increases mortality and impacts more than just the patient.5,6,7

Major Depressive Disorder (MDD) is a serious and debilitating condition that affects more than 2 million adults in the UK.8,9 People living with MDD may experience significant distress and impaired cognitive and physical function, such as disturbed sleep or appetite.10,11 Depression is a leading cause of disability and disease burden worldwide according to the World Health Organization.12

Breaking Depression

Breaking Depression aims to tackle misconceptions and stigma surrounding MDD, encourage open and honest conversations about mental health, and help support people living with or caring for someone with MDD. Empowering those affected by MDD be more open about their condition and have the confidence to seek support is an important first step in the journey to recovery. The campaign has been co-created by Janssen and SANE – a mental health charity.

Multiple Sclerosis (MS) is a disease of the central nervous system (the brain and spinal cord), causing a wide range of symptoms which vary from person to person and from day to day, making the condition rather unpredictable.13 Some of the most common symptoms around the time of diagnosis are fatigue, numbness or tingling, problems with vision, mobility or balance.14 It's a lifelong condition that can sometimes cause serious disability, although it can occasionally be mild. More than 130,000 people in the UK currently live with MS.15 Relapsing forms of MS include relapsing-remitting MS (which makes up approximately 85% of all MS cases), clinically isolated syndrome and secondary progressive MS.16

Explore More

 
 
 
 

Janssen in the UK

 

 

 
 
 

Infectious Diseases & Vaccines

 

 

 
 
 

Pulmonary Hypertension

 

 

References
1. The World Health Report 2001: Mental Disorders affect one in four people. World Health Organization. Available at: https://www.who.int/news/item/28-09-2001-the-world-health-report-2001-me.... Last accessed: June 2022.
2. Sartorious N.(2013) Comorbidity of mental and physical diseases: a main challenge for medicine of the 21st century. Shanghai Arch Psychiatry. 25(2), 68–69.
3. Connell, J. et al (2012). Quality of life of people with mental health problems: a synthesis of qualitative research. Health and Quality of Life Outcomes, 10, 138.
4. Royal College of Psychiatrists: Schizophrenia. Available at: https://www.rcpsych.ac.uk/mental-health/problems-disorders/schizophrenia. Last accessed: June 2022.
5. Millier A, et al. Humanistic burden in schizophrenia: A literature review. J Psych Res 2014;54:85–93.
6. Bitter I, et al. Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study. Eur Psychiatry 2017;45:97–103.
7. Flycht L, et al. Determinants of subjective and objective burden of informal caregiving of patients with psychotic disorders. Int J Soc Psychiatry 2015;61(7):684–692.
8. McManus S, et al. (2016) Mental Health and Wellbeing in England: Adult Psychiatric Morbidity Survey 2014. Available at: https://assets.publishing.service.gov.uk/government/ uploads/system/uploads/attachment_data/file/556596/ apms-2014-full-rpt.pdf. Last accessed June 2022.
9. Office for National Statistics (2018) Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2017. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigrati.... Last Accessed: June 2022.
10. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
11. Otte, C. et al. (2016) Major depressive disorder. Nature Reviews Disease Primers volume 2, Article number: 16065.
12. World Health Organization. Depression. Available at: https://www.who.int/news-room/fact-sheets/detail/depression. Last accessed: June 2022.
13. MS Trust. MS Facts. Available at: https://mstrust.org.uk/about-ms/what-ms/ms-facts. Last accessed: June 2022.
14. National Multiple Sclerosis Society. MS Symptoms. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms. Last accessed: June 2022.
15. Prevalence and incidence of multiple sclerosis. MS Trust. Available at: https://mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis. Last accessed: June 2022.
16. National Multiple Sclerosis Society. What is MS? Types of MS. Available at: https://www.nationalmssociety.org/What-is-MS/Types-of-MS. Last accessed: June 2022.

CP-322382 | June 2022